Itamar Medical (ITMR.TA) Stock Price

Itamar Medical Price

Delisted

Revenue has compounded at 29.3% per year over the past 17 years to 41.03 M USD. Itamar Medical's net margin stands at -26.7%, up from -78.1% several years earlier.

Itamar Medical stock price

Volume
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Itamar Medical over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Itamar Medical stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Itamar Medical's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Itamar Medical Stock Price History
DateItamar Medical Price
Access this data via the Eulerpool API

Itamar Medical Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2013
13.34 M USD
-5.17 M USD
-12.92 M USD
Jan 1, 2014
16.39 M USD
-3.57 M USD
-3.28 M USD
Jan 1, 2015
16.81 M USD
-5.27 M USD
-2.25 M USD
Jan 1, 2016
18.44 M USD
-9.70 M USD
-14.40 M USD
Jan 1, 2017
20.70 M USD
-5.63 M USD
-5.30 M USD
Jan 1, 2018
24.19 M USD
-3.12 M USD
-1.73 M USD
Jan 1, 2019
31.26 M USD
-4.89 M USD
-5.27 M USD
Jan 1, 2020
41.03 M USD
-10.34 M USD
-10.94 M USD

Itamar Medical Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 15, 2026, 4:25 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
2005200620072008200920102011201220132014201520162017201820192020
4.008.0010.008.0010.0011.0012.0013.0013.0016.0016.0018.0020.0024.0031.0041.00
100.00100.0025.00-20.0025.0010.009.098.3323.0812.5011.1120.0029.1732.26
75.0075.0080.0075.0080.0072.7366.6769.2369.2368.7575.0072.2275.0075.0077.4268.29
3.006.008.006.008.008.008.009.009.0011.0012.0013.0015.0018.0024.0028.00
-4.00-1.00-5.00-8.00-1.00-1.00-5.00-3.00-5.00-9.00-5.00-3.00-4.00-10.00
-100.00-12.50-50.00-100.00-10.00-8.33-38.46-18.75-31.25-50.00-25.00-12.50-12.90-24.39
-7.00-1.00-7.00-8.00-13.002.00-1.00-12.00-3.00-2.00-14.00-5.00-1.00-5.00-10.00
75.00-85.71600.0014.2962.50-115.38-150.00-75.00-33.33600.00-64.29-80.00400.00100.00
119.74119.74100.24120.21121.11165.68143.93150.95137.38174.87191.81262.54264.11277.67332.65415.44
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Itamar Medical generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Itamar Medical retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Itamar Medical's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Itamar Medical has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Itamar Medical's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Itamar Medical stock margins

The Itamar Medical margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Itamar Medical. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Itamar Medical.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2013
68.37 %
-38.76 %
-96.85 %
Jan 1, 2014
71.03 %
-21.80 %
-19.99 %
Jan 1, 2015
73.81 %
-31.33 %
-13.37 %
Jan 1, 2016
73.00 %
-52.62 %
-78.11 %
Jan 1, 2017
75.84 %
-27.20 %
-25.61 %
Jan 1, 2018
76.33 %
-12.90 %
-7.15 %
Jan 1, 2019
77.66 %
-15.66 %
-16.85 %
Jan 1, 2020
69.97 %
-25.21 %
-26.66 %

Itamar Medical Stock Revenue, EBIT, Earnings per Share

The Itamar Medical earnings per share therefore indicates how much revenue Itamar Medical has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2013
0.10 USD
-0.04 USD
-0.09 USD
Jan 1, 2014
0.09 USD
-0.02 USD
-0.02 USD
Jan 1, 2015
0.09 USD
-0.03 USD
-0.01 USD
Jan 1, 2016
0.07 USD
-0.04 USD
-0.05 USD
Jan 1, 2017
0.08 USD
-0.02 USD
-0.02 USD
Jan 1, 2018
0.09 USD
-0.01 USD
-0.01 USD
Jan 1, 2019
0.09 USD
-0.01 USD
-0.02 USD
Jan 1, 2020
0.10 USD
-0.02 USD
-0.03 USD

Itamar Medical business model & stock analysis

Itamar Medical Ltd is a company specialized in the development and marketing of non-invasive diagnostic and monitoring solutions for sleep disorders, heart diseases, and peripheral vascular diseases. The company was founded in Israel in 1997. The history of Itamar Medical begins with the development of the PAT system (Peripheral Arterial Tone), a device that uses the peripheral arterial tonometer to measure blood flow. With this system, doctors were able to record patients' sleep for the first time and diagnose sleep disorders such as obstructive sleep apnea syndrome (OSAS) or restless leg syndrome (RLS). Over the years, the company has expanded its offerings and developed various solutions to improve the diagnosis and monitoring of heart and vascular diseases. Itamar Medical's products now include the EndoPAT, WatchPAT, and Total Sleep Solution, among others. The EndoPAT is a non-invasive medical device that measures the endothelial function state of patients. This refers to the ability of blood vessels to dilate when needed to increase blood flow. The EndoPAT allows doctors to assess the cardiovascular health status of patients and predict the risk of cardiovascular diseases. The WatchPAT is a wearable sleep monitor that wirelessly connects to an app. The device records the sleep architecture of patients and automatically detects sleep apnea episodes, which are then displayed on the app. The WatchPAT enables doctors to improve the sleep quality of patients and diagnose sleep disorders. Itamar Medical's Total Sleep Solution offers a comprehensive solution for the management of sleep disorders. The solution includes the WatchPAT tracker, the PAT procedures for sleep disorder diagnosis, and the EndoPAT procedures for assessing cardiovascular health. This combination of technologies allows doctors to treat their patients holistically and improve their cardiovascular health and sleep quality. Itamar Medical has also formed partnerships with other companies to enhance its solutions and promote new developments. Currently, the company is collaborating with Teva Pharmaceutical Industries to develop a new formulation of Sildenafil, a medication used for treating erectile dysfunction. Overall, Itamar Medical has experienced strong growth in recent years. The company has branches in the USA, Europe, and Asia and is constantly working to expand its offerings and improve its technology for the diagnosis and monitoring of heart and sleep disorders. In summary, Itamar Medical is an innovative provider of non-invasive diagnostic and monitoring solutions for sleep disorders, heart diseases, and peripheral vascular diseases. With its wide range of products and partnerships with other companies, the company is well-positioned to continue growing and expanding in the coming years.

Itamar Medical SWOT Analysis

Strengths

1. Advanced Medical Technologies: Itamar Medical Ltd is known for its innovative medical devices, particularly in the field of sleep apnea diagnosis and management. Their cutting-edge technologies provide accurate and reliable results, enabling healthcare providers to deliver better patient care.

2. Strong Market Presence: The company has established a strong market presence globally, with a wide distribution network and collaborations with healthcare institutions. This enables them to reach a large customer base and maintain a competitive edge.

3. Experienced Management Team: Itamar Medical Ltd is supported by a team of experienced professionals who have extensive knowledge and expertise in the healthcare industry. This leadership ensures effective decision-making and strategic planning.

Weaknesses

1. Dependence on Specific Product Segments: The company relies heavily on its sleep apnea diagnostic products, which may pose a risk if there is a decline in demand or if competitors introduce similar products. Diversification into other medical segments could mitigate this weakness.

2. Limited Geographical Reach: Although Itamar Medical Ltd has a global presence, its products may not be widely available in certain regions. Expanding into untapped markets could help increase market share and revenue.

Opportunities

1. Growing Demand for Sleep Apnea Diagnosis: The increasing prevalence of sleep apnea and awareness of its health risks present an opportunity for Itamar Medical Ltd to expand its customer base and market share. Developing new products or improving existing ones could capture this growing demand.

2. Technological Advancements: Continuous advancements in medical technology provide an opportunity for Itamar Medical Ltd to develop and introduce new products that address unmet needs in the healthcare industry. Staying at the forefront of technological innovation can lead to a competitive advantage.

3. Strategic Partnerships: Collaborating with healthcare providers, research institutions, and other industry stakeholders can open doors to new opportunities for research, development, and market expansion. Partnerships can also enhance the company's reputation and credibility.

Threats

1. Intense Competition: The medical device industry is highly competitive, with many established companies and new entrants vying for market share. Itamar Medical Ltd must continuously innovate and maintain its technological edge to stay ahead of competitors.

2. Regulatory Constraints: Compliance with regulations and obtaining necessary approvals for medical devices can be challenging and time-consuming. Changes in regulations or delays in approvals can impact product launches and market entry.

3. Economic Volatility: Fluctuations in the global economy can affect healthcare spending, including the purchase of medical devices. Itamar Medical Ltd needs to be prepared for potential economic downturns and adapt its strategies accordingly.

Itamar Medical Eulerpool Fair Value

Details

Fair Value Estimate

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Itamar Medical historical P/E ratio, EBIT multiple, and P/S ratio

Itamar Medical annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Itamar Medical shares outstanding

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2013
137.38 M Stocks
Jan 1, 2014
174.87 M Stocks
Jan 1, 2015
191.81 M Stocks
Jan 1, 2016
262.54 M Stocks
Jan 1, 2017
264.11 M Stocks
Jan 1, 2018
277.67 M Stocks
Jan 1, 2019
332.65 M Stocks
Jan 1, 2020
415.44 M Stocks
Price targets and forecasts for Itamar Medical are not yet available.

Itamar Medical shareholder structure

% Name
0.00690%
Dimensional Fund Advisors, Ltd.
Dimensional Fund Advisors, Ltd.
0.00339%
Dimensional Fund Advisors, L.P.
Dimensional Fund Advisors, L.P.
0.00000%
ARK Investment Management LLC
ARK Investment Management LLC

Frequently asked questions about Itamar Medical

The business model of Itamar Medical Ltd revolves around the development, manufacturing, and marketing of non-invasive medical devices for sleep apnea diagnosis and management. Itamar Medical specializes in creating innovative products that assist in the diagnosis of various sleep disorders, with a particular focus on obstructive sleep apnea. The company's flagship product, WatchPAT, is a portable and user-friendly diagnostic device that measures various physiological parameters during sleep, providing accurate and reliable results. Itamar Medical aims to enhance patient care by providing healthcare professionals with advanced diagnostic tools that improve the management and treatment of sleep-related disorders, ultimately improving patients' quality of life.

Itamar Medical Ltd is primarily active in the healthcare industry.

The main competitors of Itamar Medical Ltd in the market include leading companies such as ResMed Inc., Koninklijke Philips N.V., and Natus Medical Incorporated.

Itamar Medical Ltd is a renowned global medical technology company that focuses on the development, marketing, and distribution of medical devices for the diagnosis of sleep apnea and other sleep disorders. Founded in 1997, Itamar Medical has established itself as a leader in the field, providing innovative solutions backed by rigorous research and development. The company's flagship product, WatchPAT, is a cutting-edge diagnostic device that offers a convenient at-home alternative to traditional sleep studies. With its commitment to improving patients' lives and enhancing healthcare professionals' understanding of sleep-related conditions, Itamar Medical has gained recognition and trust worldwide.

Itamar Medical Ltd has achieved several significant milestones. The company developed the WatchPAT™ home sleep apnea test, which revolutionized the way sleep disorders are diagnosed. It also introduced the EndoPAT™ device for assessing endothelial function, helping in the detection and prevention of cardiovascular diseases. Itamar Medical has received various regulatory approvals and certifications for its products, expanding its global reach. Additionally, the company has established strategic partnerships with key players in the healthcare industry, further enhancing its market position. Through its innovative solutions and collaborations, Itamar Medical Ltd continues to make important strides in improving sleep and cardiovascular health.

Itamar Medical Ltd is primarily present in the following countries and regions: United States, Israel, Europe, and Asia.

Itamar Medical Ltd represents values of innovation, commitment to patient care, and technological advancements in the medical industry. The company's corporate philosophy focuses on providing cutting-edge solutions for the diagnosis and management of sleep apnea and other related sleep disorders. By leveraging their expertise and advanced technology, Itamar Medical Ltd aims to improve the lives of patients worldwide suffering from sleep-related conditions. With a strong emphasis on research and development, the company continuously strives to deliver high-quality and reliable products that address the unique needs of healthcare professionals and patients alike.

Itamar Medical Ltd is an Israeli company that specializes in the development and manufacturing of medical devices for the diagnosis and monitoring of sleep disorders and cardiovascular diseases. The business model of Itamar Medical is based on providing innovative technologies and solutions for the healthcare industry to improve patient's quality of life and optimize medical care. One of the main divisions of Itamar Medical is sleep medicine, where the company offers a wide range of products. This includes specialized EEG sensors like the NightWatch system, which enables easy and effective monitoring of patients. Itamar Medical also offers a home screening service for sleep-related breathing disorders, where patients are sent a portable device to monitor their sleep quality. Another important segment of Itamar Medical is cardiology, where the company offers innovative devices for the diagnosis and monitoring of cardiovascular diseases. This includes the EndoPAT system, which allows doctors to measure the function of blood vessels in patients. This is an important indicator for the presence of atherosclerosis and other heart diseases. Itamar Medical also focuses on the field of clinical information systems (CIS). The company develops medical IT solutions to optimize workflows in hospitals and doctor's offices. Itamar Medical's CIS solutions help doctors and hospital staff effectively manage patient data and make critical data quickly accessible when needed. The business model of Itamar Medical is based on the development of groundbreaking technologies that advance medical progress. The company also strives for high user-friendliness and an easily accessible user interface to enable easy integration into existing systems. By collaborating with public and private healthcare institutions, Itamar Medical can offer its products and services worldwide, thus meeting the need for effective medical care. Overall, Itamar Medical has established itself as an important player in the healthcare industry by providing innovative solutions to some of the most common medical challenges. The business model includes a wide range of products and services tailored to the needs of patients and medical professionals. Whether it's sleep disorders, cardiovascular diseases, or medical IT solutions, Itamar Medical aims to improve the quality of life for patients worldwide.

The revenue cannot currently be calculated for Itamar Medical.

The profit cannot currently be calculated for Itamar Medical.

The P/E ratio cannot be calculated for Itamar Medical at the moment.

The P/S cannot be calculated for Itamar Medical currently.

The Eulerpool Quality Score for Itamar Medical is 4/10.

The ISIN of Itamar Medical is IL0011024580. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Itamar Medical is A1CZAF. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Itamar Medical is ITMR.TA. The ticker symbol is used to trade Itamar Medical shares on the stock exchange.

Itamar Medical is assigned to the 'Health' sector.

The dividends of Itamar Medical are distributed in USD.

All fundamentals and in-depth analysis of Itamar Medical

Our stock analysis for Itamar Medical stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Itamar Medical. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.